Lenire Now Included in U.S. ENT Clinical Practice Guidelines – First New Treatment Added by American Academy of Otolaryngology Since Establishment of the Academy’s Tinnitus Guidelines

The American Academy of Otolaryngology has included Lenire as a treatment option in the Academy’s new Clinical Practice Guidelines for Tinnitus

Continue reading at AudiologyOnline →

Audiologists treating tinnitus patients should be aware that Lenire (bimodal neuromodulation) is now a guideline-recognized option; clinicians with eligible patients may consider discussing or referring for this therapy, though it is not yet a first-line recommendation.

Guideline inclusion by the AAO-HNS is a significant regulatory milestone that legitimizes bimodal neuromodulation as a tinnitus treatment and is likely to influence insurance coverage decisions and referral patterns across ENT and audiology practices.

1. 01The AAO-HNS has added Lenire to its Clinical Practice Guidelines for Tinnitus — the first new treatment inclusion since the guidelines were established.
2. 02Lenire uses bimodal neuromodulation, combining tongue stimulation and sound to reduce tinnitus severity.
3. 03Guideline inclusion does not equate to a first-line recommendation but formally recognizes clinical validity.
4. 04This decision may accelerate insurance coverage and reimbursement discussions for Lenire in the U.S.
5. 05Audiologists should be prepared for increased patient inquiries about Lenire following media coverage of this update.